

---

FOR IMMEDIATE RELEASE

# **Paul, Weiss Welcomes Leading Antitrust Practitioner in Washington**

**New York and Washington, D.C., February 2, 2026**— Paul, Weiss, Rifkind, Wharton & Garrison LLP announced today that Jesse Solomon has joined the firm as a partner in the Antitrust Practice, resident in Washington. A prominent antitrust practitioner, Solomon advises clients on domestic and global merger clearance, complex antitrust investigations and non-merger conduct matters.

“Jesse has significant experience across the spectrum of critical antitrust matters, and we are thrilled to welcome him to our growing Washington antitrust team,” said Paul, Weiss Chairman Brad S. Karp. “His proven ability to secure clearances for multibillion-dollar mergers will be an invaluable asset to our clients as they navigate the increased global regulatory scrutiny of major transactions.”

“We are delighted to welcome Jesse, whose stature in the antitrust bar and extraordinary track record before the FTC and DOJ set him apart,” said Scott A. Sher, global co-chair of the Antitrust Practice. “His proven success guiding clients through complex merger clearances and investigations will be a tremendous asset to our clients, who require the most sophisticated antitrust counsel.”

Solomon has advised on some of the most significant and complex transactions and investigations in recent history across a range of industries, including pharmaceuticals, healthcare, technology, chemicals and consumer products. He regularly represents clients on antitrust and non-merger conduct investigations before the Federal Trade Commission and the U.S. Department of Justice. In his M&A advisory practice, he develops strategies for securing merger clearance of transactions across jurisdictions worldwide.

Solomon has obtained clearance for numerous multibillion-dollar transactions. Some of Solomon’s notable representations in the life sciences and healthcare space include Aetna in connection with its sale to CVS Health; Shire on its acquisition by Takeda; and AstraZeneca, Bristol Myers Squibb and GSK plc on various transactions. His representations in other industries include ICM Partners on its acquisition of Creative Artists Agency following a lengthy DOJ review; Campbell Soup in connection with its acquisition of Sovos Brands; and Nuvei on its acquisition of Paya Holdings. In addition, Solomon has led large-scale conduct investigations and litigations, including a recent impact litigation for Syngenta.

Solomon has received numerous accolades and recognitions throughout the course of his career. He has been recognized by *Chambers USA* for Antitrust in Washington, D.C. and

## **CONTACT**

**Laura Van Drie**  
Director of Communications  
+1 212 373 2131  
[lvandrie@paulweiss.com](mailto:lvandrie@paulweiss.com)

New York  
Brussels  
Hong Kong  
London  
Los Angeles  
San Francisco  
Tokyo  
Toronto  
Washington, DC  
Wilmington

*Legal 500 U.S.* as a Next Generation Partner for Antitrust: Merger Control and was previously named a “D.C. Rising Star” by the *National Law Journal*.

He earned his J.D. from UC Berkeley School of Law, where he was elected to the Order of the Coif and served as Senior Notes and Comments Editor of the *California Law Review*. He received an M.A. and B.A., *summa cum laude*, in English Literature from Emory University.

The Paul, Weiss Antitrust Practice advises clients on a full range of global antitrust matters, including antitrust regulatory clearance, government investigations, private litigation, and counseling and compliance. The firm represents clients before antitrust and competition authorities in the United States, the European Union, the United Kingdom and other jurisdictions around the world.

## **About Paul, Weiss**

Paul, Weiss, Rifkind, Wharton & Garrison LLP is a premier firm of more than 1,000 lawyers with diverse backgrounds, personalities, ideas and interests who provide innovative and effective solutions to our clients’ most complex legal and business challenges. The firm represents many of the world’s largest and most important public and private corporations, asset managers and financial institutions, as well as clients in need of pro bono assistance.